Fedratinib
Fedratinib
Fedratinib (pronunciation: /fɛˈdrætɪnɪb/) is a selective inhibitor of the Janus kinase 2 (JAK2) used for the treatment of myelofibrosis, a rare type of bone marrow cancer.
Etymology
The name "Fedratinib" is derived from its chemical structure and its function. The prefix "Fedra-" is a modification of the chemical name, and "-tinib" is a common suffix for tyrosine kinase inhibitors.
Usage
Fedratinib is used to treat adults with myelofibrosis, a rare type of bone marrow cancer. It is a type of Janus kinase 2 (JAK2) inhibitor, which works by blocking the action of JAK2, a protein that contributes to cell growth and division. By inhibiting JAK2, fedratinib can slow the growth of cancer cells.
Related Terms
- Janus kinase 2 (JAK2) inhibitor: A type of drug that blocks the action of JAK2, a protein that contributes to cell growth and division.
- Myelofibrosis: A serious bone marrow disorder that disrupts your body's normal production of blood cells.
- Tyrosine kinase inhibitors: A type of drug that blocks the action of enzymes known as tyrosine kinases, which are involved in many cell functions, including cell signaling, growth, and division.
Side Effects
Common side effects of Fedratinib include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include severe anemia and thrombocytopenia.
Precautions
Before starting Fedratinib treatment, patients should inform their healthcare provider about all their medical conditions, including if they have liver or kidney problems, are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed.
External links
- Medical encyclopedia article on Fedratinib
- Wikipedia's article - Fedratinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski